Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX) has been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $61.0833.

A number of equities analysts have weighed in on the stock. Barclays dropped their target price on shares of Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, December 17th. Cantor Fitzgerald dropped their price objective on shares of Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating for the company in a research report on Tuesday, December 2nd. UBS Group reiterated a “buy” rating and issued a $57.00 price objective on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Bank of America dropped their target price on Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a research report on Tuesday, December 2nd. Finally, Wolfe Research began coverage on Janux Therapeutics in a report on Tuesday, November 18th. They issued a “peer perform” rating on the stock.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, insider Charles M. Winter sold 2,401 shares of Janux Therapeutics stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $32,965.73. Following the completion of the sale, the insider owned 77,721 shares of the company’s stock, valued at approximately $1,067,109.33. The trade was a 3.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Andrew Hollman Meyer sold 1,879 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $25,798.67. Following the sale, the insider owned 83,095 shares of the company’s stock, valued at $1,140,894.35. The trade was a 2.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 42,364 shares of company stock worth $972,185 over the last 90 days. Insiders own 29.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Osaic Holdings Inc. lifted its stake in Janux Therapeutics by 704.6% in the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after buying an additional 3,037 shares during the period. Virtus Investment Advisers LLC grew its position in shares of Janux Therapeutics by 37.9% during the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after buying an additional 1,011 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after acquiring an additional 2,502 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Janux Therapeutics by 25.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after acquiring an additional 820 shares during the period. Finally, Winthrop Capital Management LLC acquired a new position in Janux Therapeutics during the third quarter valued at approximately $106,000. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Stock Performance

Shares of JANX stock opened at $14.16 on Wednesday. The firm has a fifty day moving average of $21.05 and a 200-day moving average of $23.43. The stock has a market cap of $851.72 million, a price-to-earnings ratio of -8.43 and a beta of 2.88. Janux Therapeutics has a 52-week low of $13.26 and a 52-week high of $50.89.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.21. The company had revenue of $10.00 million for the quarter, compared to the consensus estimate of $3.07 million. On average, sell-side analysts predict that Janux Therapeutics will post -1.38 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.